Cadila Healthcare Ltd (Zydus Cadila), and its subsidiary Zydus Pharmaceuticals (USA) Inc., a generic pharmaceutical company in the United States, on Tuesday, announced that they have finalised an agreement with Supernus Pharmaceuticals, Inc., to settle all outstanding patent litigation related to Trokendi XR® (topiramate) extended-release capsules.

Under the terms of the agreement, Supernus grants Zydus a license to market Zydus’ generic version of Trokendi XR® (topiramate) extended-release capsules beginning on January 1, 2023, or earlier under certain circumstances, according to a release here.

Other terms of the settlement were not disclosed.